Research programme: radiolabeled ACE diagnostics - Molecular Insight PharmaceuticalsAlternative Names: MIP-190
Latest Information Update: 23 Jan 2013
At a glance
- Originator Molecular Insight Pharmaceuticals
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Heart failure
Most Recent Events
- 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
- 25 Mar 2008 Preclinical development is ongoing
- 08 Feb 2007 Preclinical trials in Diagnostic imaging in USA (unspecified route)